The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

The Food and Drug Administration (FDA) has approved lenacapavir, an injectable drug that has been shown to act as ...

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

The recent FDA approval of lenacapavir is encouraging in its promise of long-term HIV prevention but might not be available for the vast majority of people in the US.

WHO celebrates FDA's nod to injectable lenacapavir for HIV prevention, promising easier adherence with biannual doses.

Lenacapavir is an antiretroviral medicine that helps prevent 99.9 per cent of all HIV transmission, according to studies.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...